We are a novel drug R&D company focusing on discovering, developing and commercializing innovative therapeutics in oncology and autoimmune diseases.  With a team of around 200 scientists and staff, our pipeline is comprised of novel oral compounds for cancer and inflammation in development in North America, Europe, Australia and Greater China.

These products include a novel oral compound for inflammatory bowel disease, which is entering Phase III for UC (ulcerative colitis) in the US & Europe; a novel first-in-class IL-10 modulating inflammation compound that completed phase I in Australia; three NCEs in oncology in Phase I in China and two NCEs entering Phase I soon.  Multiple NCEs are also in preclinical development.

After founding the company in 2002, we have built one of the largest and most experienced new drug R&D teams in China.  We are led by a first class senior management team, all of whom have many years of experience succeeding at large US pharmaceutical and biotech companies. Our strategic partnerships have involved global, innovative companies such as Johnson & Johnson, Eli Lilly and Merck Serono in both oncology and inflammation.